Next-Generation Breast Cancer Diagnostic and Screening market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Next-Generation Breast Cancer Diagnostic and Screening market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Segment by Application
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers
By Company
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
